Cancer immunotherapy

Celyad Oncology to Participate in a Fireside Chat at the JMP Securities Hematology Summit

Tuesday, December 1, 2020 - 9:01pm

A live and archived webcast of the presentation will be available in the Events section of the Celyad Oncology website.

Key Points: 
  • A live and archived webcast of the presentation will be available in the Events section of the Celyad Oncology website.
  • Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer.
  • Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY.
  • This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995.

City of Hope Has Developed a Cancer-killing Virus That Activates Immune System, Helps Eliminate Colon Cancer

Tuesday, December 1, 2020 - 3:00pm

A cancer-killing virus that City of Hope scientists developed could one day improve the immune systems ability to eradicate tumors in colon cancer patients, reports a new study in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.

Key Points: 
  • A cancer-killing virus that City of Hope scientists developed could one day improve the immune systems ability to eradicate tumors in colon cancer patients, reports a new study in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.
  • Our oncolytic virus trains the immune system to target a specific cancer cell.
  • City of Hope has licensed CF33 to Imugene Limited , a company developing novel therapies that activate the immune system against cancer.
  • City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases.

Dragonfly Therapeutics Announces Merck Opt-In of TriNKET™ Immunotherapy Candidate for Patients with Solid Tumors

Tuesday, December 1, 2020 - 3:00pm

Merck executes option to license its first immunotherapy candidate from the companies' 2018 collaboration for solid tumor targets.

Key Points: 
  • Merck executes option to license its first immunotherapy candidate from the companies' 2018 collaboration for solid tumor targets.
  • WALTHAM, Mass., Dec. 1, 2020 /PRNewswire/ --Dragonfly Therapeutics, Inc. ("Dragonfly"), today announced that Merck, known as MSD outside the United States and Canada, has licensed its first TriNKET immunotherapy candidate from Dragonfly.
  • Merck and Dragonfly's collaboration, initially focused on a number of solid tumor targets, began in October 2018.
  • Under the agreement Merck has exercised its option to license exclusive worldwide intellectual property rights on its first immunotherapy candidate developed using the TriNKETtechnology platform and Dragonfly has received an undisclosed payment associated with this milestone.

Dragonfly Therapeutics Announces Merck Opt-In of TriNKET™ Immunotherapy Candidate for Patients with Solid Tumors

Tuesday, December 1, 2020 - 3:00pm

Merck executes option to license its first immunotherapy candidate from the companies' 2018 collaboration for solid tumor targets.

Key Points: 
  • Merck executes option to license its first immunotherapy candidate from the companies' 2018 collaboration for solid tumor targets.
  • WALTHAM, Mass., Dec. 1, 2020 /PRNewswire/ --Dragonfly Therapeutics, Inc. ("Dragonfly"), today announced that Merck, known as MSD outside the United States and Canada, has licensed its first TriNKET immunotherapy candidate from Dragonfly.
  • Merck and Dragonfly's collaboration, initially focused on a number of solid tumor targets, began in October 2018.
  • Under the agreement Merck has exercised its option to license exclusive worldwide intellectual property rights on its first immunotherapy candidate developed using the TriNKETtechnology platform and Dragonfly has received an undisclosed payment associated with this milestone.

IN8bio to Present at Upcoming December Investor Conferences

Monday, November 30, 2020 - 9:00pm

IN8bio is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.

Key Points: 
  • IN8bio is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.
  • IN8bios technology incorporates drug-resistant immunotherapy (DRI), which has been shown in preclinical studies to function in combination with therapeutic levels of chemotherapy.
  • IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma, which is a difficult to treat brain tumor that progresses rapidly, and INB-100 for the treatment of patients with acute leukemia undergoing hematopoietic stem cell transplantation.
  • For more information about the Company and its programs, visit www.IN8bio.com.

Taiwan-based Enterprises AP Biosciences and LuminX Novel Cancer Treatments

Monday, November 30, 2020 - 4:00pm

Currently, there are two companies in Taiwan that are accelerating the development of these therapies and provide innovative treatments.

Key Points: 
  • Currently, there are two companies in Taiwan that are accelerating the development of these therapies and provide innovative treatments.
  • AP Biosciences (APBio)is a discovery-stage immunotherapeutic company developing mono- and bi-specific antibodies for various forms of treatment.
  • One of the company's major products, T-Cube bsAbs, involves bi-specific antibodies that lead T cells to cancer cells.
  • They do so by bridging the T cells to unique antigens found on the surface of cancer cells, resulting in T cell activation which kills the cancer cells.

Report from extraordinary general meeting in Active Biotech and adjustment of previously communicated timetable for the rights issue

Monday, November 30, 2020 - 2:30pm

Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership.

Key Points: 
  • Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership.
  • Active Biotech currently holds three projects in its portfolio: Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a Phase 1/2 clinical program in patients with advanced solid tumors.
  • Laquinimod is advancing to phase 2 for treatment of non-infectious uveitis during second half of 2021.
  • This information was submitted for publication, through the agency of the contact person set out above, at 15.30 p.m. CET on November 30, 2020.

Iovance Biotherapeutics to Present at Upcoming Conferences in December

Monday, November 30, 2020 - 12:21pm

Tumor infiltrating lymphocyte (TIL) therapy uses a patients own immune cells to attack cancer.

Key Points: 
  • Tumor infiltrating lymphocyte (TIL) therapy uses a patients own immune cells to attack cancer.
  • TIL cells are extracted from a patients own tumor tissue, expanded through a proprietary process, and infused back into the patient.
  • The company has completed dosing in the pivotal study in patients with metastatic melanoma and cervical cancer.
  • A clinical study to investigate Iovance T cell therapy for blood cancers called peripheral blood lymphocyte (PBL) therapy is open to enrollment.

Fate Therapeutics to Host Virtual Event at the 2020 ASH Annual Meeting

Monday, November 30, 2020 - 1:00pm

SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that management will host a virtual event entitled The Power of hnCD16 on Friday,December 4, 2020 at 4:30 PM EDT.

Key Points: 
  • SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that management will host a virtual event entitled The Power of hnCD16 on Friday,December 4, 2020 at 4:30 PM EDT.
  • The event is not an official program of the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.
  • Fate Therapeutics iPSC product platform is supported by an intellectual property portfolio of over 300 issued patents and 150 pending patent applications.
  • Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.

Corvus Announces Upcoming CPI-818 Data Presentations at the American Society of Hematology (ASH) Annual Meeting & Exposition

Monday, November 30, 2020 - 1:00pm

Hodgkin Lymphoma and T/NK Cell LymphomaClinical Studies: Poster II

Key Points: 
  • Hodgkin Lymphoma and T/NK Cell LymphomaClinical Studies: Poster II
    Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
  • These product candidates are being studied in ongoing Phase 1b/2 and Phase 1/1b clinical trials in patients with a wide range of advanced solid tumors.
  • CPI-006 is being evaluated in a multicenter Phase 1/1b clinical trial as a single agent, in combination with ciforadenant and pembrolizumab.
  • The Company is conducting a Phase 1 dose escalation trial in patients with refractory T-cell lymphomas.